Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT07353437 Sponsor: Fudan University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT07353437
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 18 and 75 years old.
  • People with a good general level of physical fitness and ability to carry out daily activities (a medical performance score of 0 or 1 out of 4).
  • People whose breast cancer has been confirmed by a tissue sample (biopsy) as an invasive cancer, regardless of the specific type.
  • People whose surgery removed all visible and detectable cancer, with no cancer left behind.
  • People who meet one of the following treatment history and pathology combinations after surgery: triple-negative breast cancer who received pre-surgery chemotherapy (at least 6 cycles) but did not achieve a complete response; hormone receptor-positive (ER and/or PgR-positive), HER2-negative breast cancer who received pre-surgery chemotherapy or hormone therapy (at least 6 cycles) but did not achieve a complete response and still had cancer in the lymph nodes; triple-negative breast cancer who did not receive pre-surgery treatment and whose tumour was larger than a certain size or had spread to at least one lymph node; or hormone receptor-positive, HER2-negative breast cancer who did not receive pre-surgery treatment and had 4 or more positive lymph nodes, or 1–3 positive lymph nodes alongside at least one high-risk feature such as a tumour 5 cm or larger, a high-grade tumour, or a high Ki-67 score (a marker of how quickly cancer cells are growing) (confirm with trial site).
  • People who have been found, through genetic testing, to carry a harmful or potentially harmful change (mutation) in one of a specific list of genes involved in DNA repair, including PALB2, RAD51C, RAD51D, BRIP1, and others (confirm with trial site for the full gene list).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have cancer in both breasts, or who have a non-invasive form of breast cancer such as DCIS or LCIS.
  • People whose cancer has spread to other parts of the body (metastatic disease).
  • People who have a suspicious but unconfirmed finding in the opposite breast that still requires a biopsy to check.
  • People who have previously received treatment for advanced or metastatic breast cancer.
  • People who have taken tamoxifen, raloxifene, or aromatase inhibitors to lower their risk of developing breast cancer, or who have had their ovaries surgically removed as a preventive measure, within the past 2 years.
  • People who have had another cancer (other than a certain type of non-melanoma skin cancer or cervical carcinoma in situ) within the past 5 years, including cancer in the opposite breast.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026

Contact this trial

Phone: 021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
31 March 2026
Est. completion
31 December 2031

Primary endpoints

iDFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov